Sandra V.
- Country
- France
- Department
- Neurologie
Research Overview
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- TRIO: A prospective randomized Trial of non-inferiority comparing RItuximab versus Ocrelizumab in relapsing-remitting multiple sclerosis.
- Randomized open-label trial comparing 2-month versus 6-month schedules of adjuvanted recombinant VZV glycoprotein E vaccine in MS and NMOSD patients on anti‑CD20 therapy
Data & Insights
Has run more than one trial at 230 of 420 partner sites.
Specializations
Multiple Sclerosis Research
This investigator specializes in studying various forms of multiple sclerosis (MS), with particular emphasis on both relapsing and progressive forms of the disease.
- Relapsing Multiple Sclerosis (RMS)
- Primary Progressive Multiple Sclerosis (PPMS)
- Secondary Progressive Multiple Sclerosis (SPMS)
The research focuses on evaluating novel therapeutic approaches and treatment efficacy in different MS populations.
Treatment Innovations
The investigator explores innovative therapeutic agents including monoclonal antibodies and targeted molecular therapies for MS treatment.
- Anti-CD20 Therapies
- Bruton's Tyrosine Kinase Inhibitors
- Novel Therapeutic Approaches
Research encompasses evaluation of long-term safety and efficacy profiles of various treatment modalities.
Clinical Outcomes
The investigator studies disease progression markers and therapeutic effectiveness in neurological conditions.
- Disability Progression Assessment
- Treatment Response Monitoring
- Long-term Patient Outcomes
Focus includes evaluation of disease activity and patient response to various therapeutic interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.